Log in
Enquire now

List of CanBas Co., Ltd. patents

List of CanBas Co., Ltd. patents
List of Sphero patents
List of bertec corporation patents
List of Adherex Technologies patents
List of dynamic program analysis patents
List of SBIR/STTR awards granted to NEPHROPATHOLOGY ASSOCIATES, PLC
Patents where
Current Assignee
Name
is
CanBas Co., Ltd.CanBas Co., Ltd.
Name
Description
Patent Applicant
Current Assignee
Inventor
Patent Jurisdiction
Patent Number
Date of Patent
‌
US Patent 7407985 Compounds that abrogate DNA damage induced cell cycle G2 checkpoint and/or augment anti-cancer activity of DNA-damaging treatments

Patent 7407985 was granted and assigned to CanBas Co., Ltd. on August, 2008 by the United States Patent and Trademark Office.

CanBas Co., Ltd.
CanBas Co., Ltd.
United States Patent and Trademark Office
United States Patent and Trademark Office
7407985
August 5, 2008
‌
US Patent 7125842 Anti-fungal compounds and methods of use

Patent 7125842 was granted and assigned to CanBas Co., Ltd. on October, 2006 by the United States Patent and Trademark Office.

CanBas Co., Ltd.
CanBas Co., Ltd.
United States Patent and Trademark Office
United States Patent and Trademark Office
7125842
October 24, 2006
‌
US Patent 8084454 Compounds with anti-cancer activity

Patent 8084454 was granted and assigned to CanBas Co., Ltd. on December, 2011 by the United States Patent and Trademark Office.

CanBas Co., Ltd.
CanBas Co., Ltd.
United States Patent and Trademark Office
United States Patent and Trademark Office
8084454
December 27, 2011
‌
US Patent 7652042 Compounds that abrogate DNA damage induced cell cycle G2 checkpoint and/or augment anti-cancer activity of DNA-damaging treatments

Patent 7652042 was granted and assigned to CanBas Co., Ltd. on January, 2010 by the United States Patent and Trademark Office.

CanBas Co., Ltd.
CanBas Co., Ltd.
United States Patent and Trademark Office
United States Patent and Trademark Office
7652042
January 26, 2010
‌
US Patent 9221872 Peptides and peptidomimetics in combination uses and treatments for cancer patient subpopulations

Patent 9221872 was granted and assigned to CanBas Co., Ltd. on December, 2015 by the United States Patent and Trademark Office.

CanBas Co., Ltd.
CanBas Co., Ltd.
CanBas Co., Ltd.
CanBas Co., Ltd.
United States Patent and Trademark Office
United States Patent and Trademark Office
9221872
December 29, 2015
‌
US Patent 10149887 Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment

Patent 10149887 was granted and assigned to CanBas Co., Ltd. on December, 2018 by the United States Patent and Trademark Office.

CanBas Co., Ltd.
CanBas Co., Ltd.
CanBas Co., Ltd.
CanBas Co., Ltd.
United States Patent and Trademark Office
United States Patent and Trademark Office
10149887
December 11, 2018
‌
US Patent 7358046 Sensitivity test to predict efficacy of anti-cancer therapies

Patent 7358046 was granted and assigned to CanBas Co., Ltd. on April, 2008 by the United States Patent and Trademark Office.

CanBas Co., Ltd.
CanBas Co., Ltd.
United States Patent and Trademark Office
United States Patent and Trademark Office
7358046
April 15, 2008
‌
US Patent 7629364 Compounds that abrogate DNA-damage-induced cell cycle G2 checkpoint and/or augment anti-cancer activity of DNA-damaging treatments

Patent 7629364 was granted and assigned to CanBas Co., Ltd. on December, 2009 by the United States Patent and Trademark Office.

CanBas Co., Ltd.
CanBas Co., Ltd.
United States Patent and Trademark Office
United States Patent and Trademark Office
7629364
December 8, 2009
‌
US Patent 7851592 Compositions and methods for inhibiting G2 cell cycle arrest and sensitizing cells to DNA damaging agents

Patent 7851592 was granted and assigned to CanBas Co., Ltd. on December, 2010 by the United States Patent and Trademark Office.

CanBas Co., Ltd.
CanBas Co., Ltd.
United States Patent and Trademark Office
United States Patent and Trademark Office
7851592
December 14, 2010
‌
US Patent 8415357 Compounds with anti-cancer activity

Patent 8415357 was granted and assigned to CanBas Co., Ltd. on April, 2013 by the United States Patent and Trademark Office.

CanBas Co., Ltd.
CanBas Co., Ltd.
United States Patent and Trademark Office
United States Patent and Trademark Office
8415357
April 9, 2013
‌
US Patent 6995135 Peptides and peptidomimetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments

Patent 6995135 was granted and assigned to CanBas Co., Ltd. on February, 2006 by the United States Patent and Trademark Office.

CanBas Co., Ltd.
CanBas Co., Ltd.
United States Patent and Trademark Office
United States Patent and Trademark Office
6995135
February 7, 2006
‌
US Patent 7030111 Compounds that abrogate DNA-damage-induced cell cycle G2 checkpoint and/or augment the anti-cancer activity of DNA damaging treatments

Patent 7030111 was granted and assigned to CanBas Co., Ltd. on April, 2006 by the United States Patent and Trademark Office.

CanBas Co., Ltd.
CanBas Co., Ltd.
United States Patent and Trademark Office
United States Patent and Trademark Office
7030111
April 18, 2006
‌
US Patent 6881575 Compositions and methods for inhibiting G2 cell cycle arrest and sensitizing cells to DNA damaging agents

Patent 6881575 was granted and assigned to CanBas Co., Ltd. on April, 2005 by the United States Patent and Trademark Office.

CanBas Co., Ltd.
CanBas Co., Ltd.
United States Patent and Trademark Office
United States Patent and Trademark Office
6881575
April 19, 2005
13 results
0 selected
13 results
0 selected
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us